For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

CareASSIST Patient Support Program

CareASSIST™ logo

Resources and support for your eligible patients

CareASSIST offers access support for eligible patients prescribed JEVTANA.

If your patients have commercial insurance, they may qualify for the CareASSIST Copay Program and pay as little as $0 out of pocket for JEVTANA. Learn More.

Download enrollment form 

CareASSIST™ can help determine insurance coverage and options

Access and Reimbursement

Assistance navigating the insurance
process, including benefits investigations,
claims assistance, and information about
prior authorizations and appeals.

See what's offered 

Eligible patients may qualify to receive JEVTANA (cabazitaxel) at reduced to no cost

Financial Assistance

CareASSIST offers programs and
services that can help eligible
patients with the cost of JEVTANA.

For patients with commercial insurance  For patients with no insurance
or who lack coverage 

CareASSIST™ can identify other resources and support that may be available

Resource Support

Information on independent support
services for patients and caregivers, as
well as product ordering and
replacement information.

Find support 

CareASSIST™ logo

To learn more about CareASSIST



  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave

You are leaving to view another Sanofi Genzyme Corporation website.